Blog - Page 31 of 5386 - QualityStocks

WednesdayMay 14, 2025 9:30 am

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Hits FDA Milestone and Expands Strategic Partnerships in Q1 Update

HeartBeam (NASDAQ: BEAT) reported Q1 2025 results highlighted by successful completion of the VALID-ECG pivotal study, supporting its 510(k) submission for 12-lead ECG synthesis software and confirming productive ongoing FDA discussions. The company launched an Early Access Program, signed a strategic partnership with AccurKardia to integrate its FDA-cleared AccurECG(TM) software, added two new U.S. patents to bring its IP total to 20, appointed CEO Robert Eno to its board, and raised $11.5 million through a public offering to support commercialization plans. To view the full press release, visit https://ibn.fm/06UMF About HeartBeam Inc. HeartBeam is a medical technology company dedicated to transforming…

WednesdayMay 14, 2025 9:10 am

QualityStocksNewsBreaks – Ucore Rare Metals Inc. (TSXV: UCU) (OTCQX: UURAF) Expands North American REE Refining Plans as RapidSX(TM) Nears Commissioning

Ucore Rare Metals (TSXV: UCU) (OTCQX: UURAF) is nearing the commissioning of its RapidSX(TM) Commercial Demonstration Plant in Kingston, Ontario, a key milestone in its plan to commercialize its advanced rare earth element (REE) separation technology. The company is also preparing to construct its first Strategic Metals Complex (SMC) in Louisiana, expected to process 2,000 tons of total rare earth oxides by the end of 2024 and scale to 5,000 tons in 2026. Ucore’s long-term roadmap includes additional SMCs in Alaska and Canada, alongside the development of its 100%-owned Bokan-Dotson Ridge HREE resource in Alaska. With strong U.S. and Canadian government…

WednesdayMay 14, 2025 9:00 am

ONAR Holding Corp. (ONAR) Leads the Charge in AI-Driven Marketing with Proprietary Platform

The AI marketing market is projected to surge to more than $107.5 billion by 2028 ONAR Holding recently announced the launch of ONAR Labs, its dedicated technology incubator The company also unveiled its first product offering: Cortex, an AI-powered marketing intelligence platform Artificial intelligence (“AI”) is rapidly transforming the marketing landscape, enabling businesses to deliver more personalized, efficient and data-driven campaigns. As companies seek to harness the power of AI to stay competitive, ONAR Holding Corp. (OTCQB: ONAR) is at the forefront with its innovative Cortex platform, poised to redefine the future of advertising. The adoption of AI in marketing has…

TuesdayMay 13, 2025 1:30 pm

QualityStocksNewsBreaks – MoneyShow’s Virtual Expo to Deliver Strategic Insights on Maximizing Potential in Volatile Times

MoneyShow, a leading producer of live and online financial conferences for investors, traders, and financial advisors, today announced the upcoming “Navigating Volatility, Finding Opportunity: A Virtual Expo,” set to take place May 21-22, 2025. “Investors face several key issues in this market environment. They include far-reaching U.S. tariffs, geopolitical tensions, inflation concerns, evolving trade dynamics, the potential for interest rate cuts, and the surge in safe-haven assets,” said MoneyShow’s Editor-in-Chief Mike Larson. “Our star-studded line-up of speakers will provide attendees with in-depth context to the latest market moves. They will also share highly actionable insights on minimizing risks in choppy…

TuesdayMay 13, 2025 9:50 am

QualityStocksNewsBreaks – FAVO Capital Inc. (FAVO) Converts Super Voting Shares to Support Nasdaq Uplisting Plans

FAVO Capital (OTC: FAVO), a private credit firm focused on merchant cash advances and revenue-based financing for underserved SMBs, announced the voluntary conversion of all outstanding Super Voting Series C Preferred Shares into common stock. The move simplifies the company’s capital structure, eliminates super voting rights, and aligns with public market governance standards as FAVO continues its preparations for a planned uplisting to the Nasdaq Capital Market. CEO Vincent Napolitano said the decision reflects FAVO’s commitment to transparency, best practices, and long-term value creation for shareholders. To view the full press release, visit https://ibn.fm/Qat87 About FAVO Capital Inc. FAVO Capital is…

TuesdayMay 13, 2025 9:45 am

Nutriband Inc. (NASDAQ: NTRB) Pioneers Innovative Approach to Opioid Crisis with Game-Changing Transdermal Patch

The opioid epidemic has prompted a re-evaluation of pain-management strategies, highlighting the importance of balancing effective treatment with abuse prevention Nutriband's AVERSA(TM) Fentanyl represents a significant advancement in this domain The company’s strategic development of AVERSA Fentanyl follows a structured pharmaceutical lifecycle As the opioid crisis continues to challenge public health systems, the need for innovative solutions has become increasingly apparent. Rather than relying solely on restrictive measures, companies such as Nutriband (NASDAQ: NTRB) are exploring technological advancements to mitigate abuse while ensuring patient access to necessary medications. Nutriband's development of AVERSA(TM) Fentanyl, an abuse-deterrent transdermal patch, exemplifies this forward-thinking approach…

TuesdayMay 13, 2025 9:30 am

QualityStocksNewsBreaks – Intelligent Bio Solutions Inc. (Nasdaq: INBS) Grows Revenue, Cuts Losses in Fiscal Q3 as Cartridge Sales Drive Margins

Intelligent Bio Solutions (Nasdaq: INBS), a medical technology company delivering rapid, non-invasive testing solutions, reported a 20% sequential revenue increase to $728,867 in fiscal Q3 2025, driven by growth in cartridge sales, which now account for 58% of total revenue and strengthen its recurring revenue model. Gross profit surged 91% year-over-year to $341,368, while net loss narrowed by $434,141 to $2.54 million. INBS added 35 new accounts, bringing its active customer base to over 450, and continued expanding internationally through partnerships and multilingual system upgrades. The company also secured its sixth U.S. patent and advanced regulatory efforts across key global…

TuesdayMay 13, 2025 9:20 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Secures Orphan Drug Designation Transfer for TPI 287 in Brain Cancer Indications

CNS Pharmaceuticals (NASDAQ: CNSP) announced the successful transfer of Orphan Drug Designation from Cortice Biosciences for its lead asset TPI 287, covering gliomas, pediatric neuroblastoma, and progressive supranuclear palsy. TPI 287, a microtubule-stabilizing abeotaxane, has shown potential to cross the blood-brain barrier and demonstrated encouraging results in a Phase 1 glioblastoma trial, including 3 complete and 9 partial responses among 23 evaluable patients. The company plans to initiate a Phase 2 study by year-end 2025 and highlighted the potential benefits of Orphan status, including seven years of market exclusivity upon approval. To view the full press release, visit https://ibn.fm/heTcg About…

TuesdayMay 13, 2025 9:00 am

Brera Holdings PLC (NASDAQ: BREA) Reiterates Commitment to the Successful MCO Model of Sustainable Football Investment; Continues to Grow International Media Visibility

Brera Holdings, an Ireland-based, international holding company focused on expanding its global portfolio of men’s and women’s sports clubs, has gained further recognition for the company’s commitment to its evolving model of sustainable football investment A recent Wall Street Journal article focused on the dangers of trying to apply the American sports model to English soccer by acquiring trophy assets, a lesson that some U.S. owners have finally learned Brera has successfully applied its multi-club ownership (“MCO”) approach, using its understanding and respect of English soccer’s advancement opportunities to grow and enrich its portfolio clubs, as shown with Brera’s acquisition…

TuesdayMay 13, 2025 9:00 am

QualityStocksNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Subsidiary HOPE Therapeutics to Acquire Kadima Neuropsychiatry Institute

NRx Pharmaceuticals (NASDAQ: NRXP) announced that its wholly owned subsidiary, HOPE Therapeutics(TM), has signed a definitive agreement to acquire the Kadima Neuropsychiatry Institute. Kadima, a leading California clinic for interventional psychiatry, offers treatments such as ketamine, Spravato, transcranial magnetic stimulation (TMS), and medication management for CNS disorders including suicidal depression and PTSD. The clinic is profitable and expected to serve as the clinical model for future HOPE clinics. Dr. David Feifel, Kadima’s founder and a nationally recognized leader in interventional psychiatry, will join HOPE as its first Chief Medical Innovation Officer following the closing of the acquisition, which remains subject…

Site Search

Company Search